Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria
Pediatr Allergy Immunol. 2025 Oct;36(10):e70216. doi: 10.1111/pai.70216. ABSTRACT BACKGROUND: Omalizumab is an effective treatment option for antihistamine-resistant chronic spontaneous urticaria (CSU) patients. This study aimed …